Artelo Biosciences Announces Appointment of Senior Pharmaceutical Executive Gregory R. Reyes, M.D., Ph.D., to Board of Directors
By Dr. Matthew Watson
LA JOLLA, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the appointment of drug discovery and development veteran Gregory R. Reyes, M.D., Ph.D. to the Company’s Board of Directors, effective November 30, 2020.
Continue reading here:
Artelo Biosciences Announces Appointment of Senior Pharmaceutical Executive Gregory R. Reyes, M.D., Ph.D., to Board of Directors
Related Post
- IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant - January 12th, 2021
- T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus - January 12th, 2021
- Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units - January 12th, 2021
- Qilian International Holding Group Limited Announces Pricing of Initial Public Offering - January 12th, 2021
- Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health - January 12th, 2021
- Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common... - January 12th, 2021
- Addex to Present at the Baader Helvea Swiss Equities Conference - January 12th, 2021
- iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19 - January 12th, 2021
- Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study - January 12th, 2021
- BetterLife Provides Shareholder Update and 2021 Product Development Roadmap - January 12th, 2021
- Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19 - January 12th, 2021
- Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2021 AGM of Orion Corporation - January 12th, 2021
- Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities - January 12th, 2021
- Valneva in Advanced Discussions with European Commission to Supply up to 60 Million Doses of Inactivated, Adjuvanted COVID-19 Vaccine Candidate - January 12th, 2021
- ProMIS Neurosciences Announces Strategic Priorities for 2021 - January 12th, 2021
- Adamas to Present at Upcoming H.C. Wainwright Conference - January 5th, 2021
- aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications - January 5th, 2021
- Syneos Health to Present at the 39th Annual J.P. Morgan Healthcare Conference - January 5th, 2021
- Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference - January 5th, 2021
- Checkmate Pharmaceuticals Announces Key Additions to Executive Management Team - January 5th, 2021
- Genocea to Present at the H.C. Wainwright Virtual BioConnect Conference - January 5th, 2021
- Paratek Pharmaceuticals Receives $60 Million Non-Recourse Loan from R-Bridge Healthcare Investment Advisory, Ltd., an affiliate of CBC Group - January 5th, 2021
- Ligature Therapeutics Launches, Raises USD $6M in Seed Financing - January 5th, 2021
- Radius Health Announces Change to its Board of Directors - January 5th, 2021
- Franciosi Consulting Reviewing the Science and History of Psychedelic Drug Use for Treating Depression, Anxiety and Addiction - January 5th, 2021
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons - January 5th, 2021
- Innate’s First NK Cell Engager Selected by Sanofi as Drug Candidate for Development - January 5th, 2021
- Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung... - January 5th, 2021
- Nicox Highlights Successful 2020 Development Progress and Clinical Milestones for 2021 - January 5th, 2021
- Polyphor to Take Part in Panel Discussion on Novel Oncology Targets at the LifeSci Partners 10th Annual Healthcare Corporate Access Event - January 5th, 2021
- ViGeneron signs global collaboration agreement for ophthalmic gene therapy development - January 5th, 2021
- Bavarian Nordic to Supply Smallpox Vaccines to Three European Countries - January 5th, 2021
- AB2 Bio to Participate in Orphan Disease Panel Discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event - January 5th, 2021
- Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference - January 5th, 2021
- Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine - January 5th, 2021
- Assertio Announces Transfer of Listing from Nasdaq Global Select Market to Nasdaq Capital Market - January 3rd, 2021
- Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference - January 3rd, 2021
- VAXIL Provides Update on USAMRIID and Oral Experiments - January 3rd, 2021
- Lui Franciosi Reviewing the Use of Sugar-Based Molecules as Potential Treatments for COVID-19 - January 3rd, 2021
- Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor - January 3rd, 2021
- Osmotica Pharmaceuticals plc Receives Complete Response Letter from U.S. Food and Drug Administration for Arbaclofen Extended Release Tablets - January 3rd, 2021
- Eve & Co Announces Share Consolidation - January 3rd, 2021
- Total number of shares and voting rights in Zealand Pharma at December 31, 2020 - January 3rd, 2021
- Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study - January 3rd, 2021
- Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia - January 3rd, 2021
- Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC) - January 3rd, 2021
- Avicanna Announces Exercise and Closing of Over-Allotment Option - January 3rd, 2021
- Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Trademark Application for The Complete... - January 3rd, 2021
- Tauriga Sciences Inc. Approved to be Corporate Exhibitor at 2021 CTIC Capital Pre-J.P. Morgan Healthcare Investment Summit January 9th-10th, 2021 - January 3rd, 2021
- Teligent, Inc. Announces Third Quarter 2020 Results - January 3rd, 2021
- Draft Top Tool Reviews - Go Topless! – Product Review by Mike Vaughn - January 3rd, 2021
- Vaxil’s Annual and Special Shareholders Meeting and Update on Exercise of Warrants - January 3rd, 2021
- Franciosi Consulting Assessing New Potential Treatments for Asthma and COPD - December 30th, 2020
- Nicox’s Partner Ocumension Therapeutics Initiates ZERVIATE Phase 3 Clinical Trial in China - December 30th, 2020
- Change in Number of Shares and Votes in Immunicum AB (publ) - December 30th, 2020
- Oxford Biomedica notes AstraZeneca’s COVID-19 vaccine has been authorised for emergency supply in the UK - December 30th, 2020
- Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021 - December 30th, 2020
- Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors - December 30th, 2020
- Codiak Reports Positive Initial Phase 1 Results for exoIL-12™ Demonstrating Tolerability and Absence of Systemic IL-12 Exposure in Healthy... - December 30th, 2020
- Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B - December 30th, 2020
- Morphic Therapeutic to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference - December 30th, 2020
- BioCardia Issued New U.S. Patent for Technology that Enhances Control for Cardiac Therapies - December 30th, 2020
- TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China that was Submitted by its Corporate Partners Alphamab... - December 30th, 2020
- VistaGen Announces Publication in CNS Spectrums Detailing Proposed Mechanism of Action of Its Investigational Neuroactive Nasal Sprays for Anxiety and... - December 30th, 2020
- Ocuphire to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event in Early January 2021 - December 30th, 2020
- Sorrento Announces the Submission of a Marketing Authorization Application to COFEPRIS (Mexico) for COVI-STIX™ Rapid Detection Test of SARS-CoV-2... - December 30th, 2020
- Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program - December 30th, 2020
- Adaptive Biotechnologies to Present at the 39th Annual J.P. Morgan Healthcare Conference - December 30th, 2020
- Eve & Co Announces CAD$1M Private Financing - December 30th, 2020
- Clene Nanomedicine Closes Merger with Tottenham Acquisition I Limited and Provides Corporate Update - December 30th, 2020
- Medicenna Establishes At-the-Market Sales Facility - December 30th, 2020
- MedMira Announces Product Update - December 30th, 2020
- Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health - December 28th, 2020
- Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with... - December 28th, 2020
- Orphazyme provides regulatory update on arimoclomol for NPC - December 28th, 2020
- Gritstone Oncology Announces Private Placement Financings Totaling $125 Million - December 28th, 2020
- Iovance Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021 - December 28th, 2020
- Better Choice to Begin Trading on the OTCQX - December 28th, 2020
- Y-mAbs Announces Sale of Priority Review Voucher - December 28th, 2020
- Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS) - December 28th, 2020
Global News Feed
Comments Off on Artelo Biosciences Announces Appointment of Senior Pharmaceutical Executive Gregory R. Reyes, M.D., Ph.D., to Board of Directors |
December 2nd, 2020
This author published 3404 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research